Alder Biopharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to transform the treatment paradigm in migraine. Co. is focusing on eptinezumab (ALD403). Eptinezumab is a humanized immunoglobulin G1 monoclonal antibody for calcitonin gene-related peptide ligand, a small protein and a target to drive migraine initiation, maintenance and chronification. Co.'s product candidate pipeline also includes ALD1910, a neutralizing monoclonal antibody with reactivity to that targets pituitary adenylate cyclase-activating polypeptide-38. We show 24 historical shares outstanding datapoints in our ALDR shares outstanding history coverage, used to compute ALDR market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ALDR market cap history over the course of time is important for investors
interested in comparing ALDR's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ALDR versus a peer is one thing; comparing
ALDR market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ALDR can fluctuate over the course of history.
With this page we aim to empower investors researching ALDR by allowing them to research the ALDR market cap history. |
Free ALDR Email Alerts:
Video: The Importance of Market Cap
